Docetaxel治療卵巢癌之檢視

Using Docetaxel in Patients with Epithelial Ovarian Cancer

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 侯廣瓊(Guang-Qeo Hou) ； 鄭文雄(Wen-Hsiung Chen) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2008年1期 (2008/04) Pp. 7-13

https://doi.org/10.7010/JGO.200804.0007

摘要

Docetaxel爲第二代taxane，而taxanes已被證實對治療上皮性卵巢癌有效。在體外試驗中，docetaxel比paclitaxel對細胞微小管(microtubule)有更高的結合能力，可殺死對paclitaxel有抗藥性的細胞株，表示此兩種藥物有那份不同的抗藥性。本文綜合討論docetaxel對治療卵巢癌之效果和副作用，作一回顧分析。

關鍵字

Docetaxel ； 卵巢癌

並列摘要

Taxanes are a highly active class of agents in patients with epithelial ovarian cancer. Docetaxel is the second-generation of taxane. In vitro, docetaxel binds microtubules with higher affinity compared to the paclitaxel and is capable of killing paclitaxel-resistant cell loses, suggesting a presence of non-cross resistance between these two drugs. In this article, docetaxel will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects, and evidence addressing the potential benefits of long-term treatment for epithelial ovarian cancer.

並列關鍵字

Docetaxel ； Epithelial ovarian cancer